Sensus Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined year-over-year due to loss of a major customer, but underlying growth was seen from a diversified base. New CPT codes and software initiatives are driving increased adoption, recurring revenue, and a positive outlook for sequential quarterly improvement in 2026.
Fiscal Year 2025
-
Exclusive CPT codes for SRT and IG-SRT provide reimbursement clarity, supporting broader adoption and international growth. 2025 saw lower revenues and a net loss, but a strong balance sheet and diversified customer base position the company for profitability in 2026.
-
Q3 2025 saw revenue and unit sales decline year-over-year, but new CMS reimbursement codes for SRT are expected to drive strong future demand and improve ROI for dermatology practices. The company maintains a strong cash position, anticipates international growth, and expects to reach break-even or profitability in Q4.
-
Q2 2025 saw a revenue decline due to paused domestic sales amid reimbursement uncertainty, but international demand grew and recurring revenue partially offset lower capital sales. Management expects resolution of reimbursement issues by year-end, with strong cash reserves and new market opportunities ahead.
-
Q1 2025 saw lower revenue and a net loss due to strategic investments, but a 65% increase in patient treatments under the Fair Deal Agreement signals strong future growth. Profitability is expected to return in the next three quarters as FDA revenues ramp up.
Fiscal Year 2024
-
Revenue grew 71% year-over-year to $41.8M in 2024, with record SRT-100 system shipments and ongoing profitability. The Fair Deal Agreement program is expected to drive significant recurring revenue in the second half of 2025, while strong liquidity supports continued R&D and expansion.
-
Q3 2024 saw revenues more than double year-over-year, driven by strong SRT system sales and a major Fair Deal Agreement with Platinum Dermatology Partners. Recurring revenue from these agreements is expected to ramp up in 2025, with continued expansion in domestic and international markets.
-
Q2 2024 saw revenue more than double year-over-year, driven by strong SRT system sales and the launch of the Fair Deal Agreement, with 15 contracts signed and up to 50 expected by year-end. Recurring revenue from these agreements will begin in 2025, and gross margin is projected to remain around 60%.